公开(公告)号：US07226779B2

公开(公告)日：2007-06-05

申请号：US10470784

申请日：2002-01-25

申请人： Changyu Zheng ,  Bruce J. Baum ,  Brian C. O'Connell

发明人： Changyu Zheng ,  Bruce J. Baum ,  Brian C. O'Connell

IPC分类号： C12N15/00

CPC分类号： C12N15/86 ,  C12N2710/10343 ,  C12N2810/6054 ,  C12N2830/60

摘要： An adenoviral vector is disclosed that includes two adenoviral ITRs, wherein the two adenoviral ITRs flank a packaging signal and a single retroviral LTR operably linked to a nucleic acid sequence of interest, wherein the adenoviral vector does not include a nucleic acid sequence encoding the retroviral structural proteins and wherein the adenoviral vector does not include a second retroviral LTR. In one embodiment, a method for transforming a cell is disclosed. In another embodiment, a method is disclosed for introducing a transgene into a cell with a single viral vector. In a further embodiment, a method is provided for preventing or treating disorder in a subject. A pharmaceutical composition is also provided.

摘要翻译： 公开了一种腺病毒载体，其包括两个腺病毒ITR，其中两个腺病毒ITR位于包装信号侧面，并且可操作地连接到感兴趣的核酸序列的单个逆转录病毒LTR，其中腺病毒载体不包括编码逆转录病毒结构的核酸序列 蛋白质，其中腺病毒载体不包括第二逆转录病毒LTR。 在一个实施例中，公开了一种用于转换单元的方法。 在另一个实施方案中，公开了用单一病毒载体将转基因导入细胞的方法。 在另一个实施方案中，提供了一种用于预防或治疗受试者中的疾病的方法。 还提供药物组合物。

公开(公告)号：US07618623B2

公开(公告)日：2009-11-17

申请号：US11255059

申请日：2005-10-19

申请人： Changyu Zheng ,  Brian O'Connell ,  Bruce J. Baum

发明人： Changyu Zheng ,  Brian O'Connell ,  Bruce J. Baum

IPC分类号： A61K48/00 ,  A01N63/00 ,  A01N43/04 ,  A61K31/711 ,  C12N15/861 ,  C12N15/867 ,  C12N15/33

CPC分类号： C12N15/86 ,  A61K35/13 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10344 ,  C12N2740/13043 ,  C12N2830/60

摘要： An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.

摘要翻译： 腺病毒包括腺病毒衣壳蛋白和复制缺陷型腺病毒载体，其包含5'逆转录病毒LTR核酸序列，3'逆转录病毒LTR核酸序列，编码逆转录病毒包膜蛋白部分的核酸序列， 提供5'LTR或3'LTR核酸序列，逆转录病毒包装序列和编码位于5'LTR和3'LTR之间的转基因的核酸序列。 还提供了感染该腺病毒的宿主细胞。 提供了包括腺病毒多核苷酸序列的腺病毒载体，其包含编码转基因的核酸，逆转录病毒包装信号，5'和3'逆转录病毒LTR以及部分逆转录病毒包膜多肽，其中所述腺病毒多核苷酸序列不 编码E1，E3或E4中的一个或多个。 还使用本发明的病毒或载体提供转化细胞的方法，以及将转基因导入到不能用单一病毒载体产生病毒颗粒的细胞中的方法。 还提供了使用本发明的腺病毒载体预防或治疗受试者的疾病的方法。 还提供了包含本发明的腺病毒载体和药学上可接受的载体的药物组合物。

公开(公告)号：US07052904B2

公开(公告)日：2006-05-30

申请号：US10182644

申请日：2001-01-30

申请人： Changyu Zheng ,  Brian O'Connell ,  Bruce J. Baum

发明人： Changyu Zheng ,  Brian O'Connell ,  Bruce J. Baum

IPC分类号： C12N15/861 ,  C12N15/867 ,  C12N15/63 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K35/13 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10344 ,  C12N2740/13043 ,  C12N2830/60

摘要： An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.

公开(公告)号：US20090258935A1

公开(公告)日：2009-10-15

申请号：US12488464

申请日：2009-06-19

申请人： Changyu Zheng ,  Brian O'Connell ,  Bruce J. Baum

发明人： Changyu Zheng ,  Brian O'Connell ,  Bruce J. Baum

IPC分类号： A61K48/00 ,  A61P43/00

CPC分类号： C12N15/86 ,  A61K35/13 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10344 ,  C12N2740/13043 ,  C12N2830/60

摘要： An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.

摘要翻译： 腺病毒包括腺病毒衣壳蛋白和复制缺陷型腺病毒载体，其包含5'逆转录病毒LTR核酸序列，3'逆转录病毒LTR核酸序列，编码逆转录病毒包膜蛋白部分的核酸序列， 提供5'LTR或3'LTR核酸序列，逆转录病毒包装序列和编码位于5'LTR和3'LTR之间的转基因的核酸序列。 还提供了感染该腺病毒的宿主细胞。 提供了包括腺病毒多核苷酸序列的腺病毒载体，其包含编码转基因的核酸，逆转录病毒包装信号，5'和3'逆转录病毒LTR以及部分逆转录病毒包膜多肽，其中所述腺病毒多核苷酸序列不 编码E1，E3或E4中的一个或多个。 还使用本发明的病毒或载体提供转化细胞的方法，以及将转基因导入到不能用单一病毒载体产生病毒颗粒的细胞中的方法。 还提供了使用本发明的腺病毒载体预防或治疗受试者的疾病的方法。 还提供了包含本发明的腺病毒载体和药学上可接受的载体的药物组合物。

公开(公告)号：US20060035371A1

公开(公告)日：2006-02-16

申请号：US11255059

申请日：2005-10-19

申请人： Changyu Zheng ,  Brian O'Connell ,  Bruce Baum

发明人： Changyu Zheng ,  Brian O'Connell ,  Bruce Baum

IPC分类号： C12N15/861

CPC分类号： C12N15/86 ,  A61K35/13 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10344 ,  C12N2740/13043 ,  C12N2830/60

摘要： An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.